Nuvectis Pharma, Inc. NVCT 深 滬
等待開盤 11-26 09:30:00 美东时间
6.09
+0.100
+1.67%
華盛通- 最 高6.2099
- 今 開6.01
- 成交量 7.22万股
- 最 低 5.90
- 昨 收 5.99
- 總市值 1.55亿
- 52周最高 11.52
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.44
- 委 比 84.16%
- 總股本 2545.68万
- 歷史最高 20.92
- 量 比 0.81
- 振 幅 5.17%
- 歷史最低 3.08
- 每 手 1
- 風險率 1.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvectis Pharma,To Discuss Key NXP900 Preclinical And Clinical Data To Date And Strategy For Monotherapy And Combination Components Of NXP900 Phase 1b Clinical Program At Key Opinion Leader Meeting
Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company"))), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need
11-25 21:04
Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.25) by 73.91 percent. This is a 83.33 percent decrease over losses of $(0.24) per share from
11-04 21:30
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma reported progress on NXP900 with the initiation of Phase 1b monotherapy and planned combination study, successful Phase 1a dose escalation, and completion of drug interaction study. Positive pharmacodynamic responses support once-daily dosing. Clinical data highlighted at AACR-NCI-EORTC conference. Cash runway extended to 3Q-2027. Third quarter financials showed $35.4M cash, up $16.9M, with net loss of $7.5M due to milestone and s...
11-04 12:30
Nuvectis Pharma Provides Highlights For NXP900 Poster Presentations For 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics In Boston
Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,
10-27 20:19
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma, Inc. will present two posters on NXP900 at the 2025 AACR-NCI-EORTC Conference in Boston. Gerald Falchook, MD will discuss clinical safety, pharmacokinetics, and cytochrome P450 interactions, while Asier Unciti-Broceta will present on NXP900's efficacy in FAT1 mutated models. Both posters will be displayed during Poster Session A on October 23, 2025.
10-16 12:00
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez, a seasoned biotech executive with over 30 years of experience in healthcare, finance, and industry, joins Nuvectis as it advances its Phase 1b program for NXP900, an innovative precision medicine targeting advanced and treatment-resistant cancers. Ron Bentsur, Nuvectis' CEO, highlighted Dr. Sanchez's expertise and his potent...
09-25 12:00
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma, Inc. announced its participation in the upcoming H.C. Wainwright Global Investment Conference. Ron Bentsur, the company's CEO, will deliver a presentation on September 5, 2025, available for on-demand viewing. The company will also engage in virtual one-on-one meetings from September 8-10, 2025. Nuvectis specializes in developing precision medicines for unmet medical needs in oncology, with two clinical-stage drug candidates: NXP...
09-04 11:30
13F持仓新鲜出炉！巴菲特减持苹果，贝莱德、高盛买入硬核科技股
近日，各大机构向美国证券交易委员会(SEC)陆续提交13F报告，披露了二季度所持美股股票和持仓规模。 其中，股神巴菲特15.7亿重仓医疗巨头、继续减持苹果，高瓴...
08-15 09:16
Nuvectis Pharma (NVCT) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Ph...
08-12 22:15
Nuvectis Launches Phase 1b Trial Of NXP900 In Advanced Solid Tumors And Resistant NSCLC
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and
08-12 04:44
